Biocon Ltd 2022 AR2
The report highlights Biocon's transition into Biocon 5.0, focusing on technology-enabled, future-ready biopharmaceuticals leadership. Key achievements in FY22 include the historic U.S. approval of the world's first interchangeable biosimilar, insulin glargine, and a landmark agreement to acquire Viatris' global biosimilars business. The company also entered a strategic alliance with Serum Institute Life Sciences to expand into vaccines. In terms of sustainability, Biocon debuted on the DJSI Emerging Markets Index, increased its green power share to 54% of total energy consumption, and achieved significant carbon footprint reductions and water savings.
Company: Biocon Ltd
Sector: Health Care
Country: India
Year: 2022
Type: AR2
Pages: 340
Biocon Ltd
Annual Report
The report highlights Biocon's transition into Biocon 5.0, focusing on technology-enabled, future-ready biopharmaceuticals leadership. Key achievements in FY22 include the historic U.S. approval of the world's first interchangeable biosimilar, insulin glargine, and a landmark agreement to acquire Viatris' global biosimilars business. The company also entered a strategic alliance with Serum Institute Life Sciences to expand into vaccines. In terms of sustainability, Biocon debuted on the DJSI Emerging Markets Index, increased its green power share to 54% of total energy consumption, and achieved significant carbon footprint reductions and water savings.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Employees